ADDED
Upon the consummation of the SL Bio Business Combination, each of the Company and SL Bio will become a subsidiary of PubCo, and the Company s shareholders and SL Bio s shareholders will receive ordinary shares, par value US$1.00 per share, of PubCo ( PubCo Ordinary Shares ) as consideration and become the shareholders of PubCo.
The PubCo Ordinary Shares are expected to be listed and traded on the Nasdaq Stock Market LLC following the consummation of the SL Bio Business Combination.
In connection with the SL Bio Business Combination, PubCo filed with the SEC a registration statement on Form F-4 (File No.
On February 12, 2026, the Company held an extraordinary general meeting (the Business Combination EGM ) in connection with the SL Bio Business Combination.
Amended M A Proposal: the shareholders approved, ratified and confirmed in all respects the amendment and restatement of memorandum and articles of association of PubCo.
Sole Director Appointment Proposal: the shareholders approved, ratified and confirmed in all respects the appointment of William Wang Ching-Dong as the sole director of HSPT, with effect from the First Merger Effective Time (as defined in the Business Combination Agreement).
In connection with the Business Combination EGM, 3,502,404 ordinary shares of HSPT were rendered for redemption, which will be redeemed upon and following the consummation of the Business Combination.
In connection with the Business Combination, PubCo entered into subscription agreements (the Subscription Agreements and the transactions contemplated under the Subscription Agreements, the PIPE Financing ) with certain investors (the PIPE Investors ), pursuant to which the PIPE Investors have committed to purchase an aggregate of 780,000 units of PubCo (the PubCo Units ), in a private placement for a purchase price of $10.00 per PubCo Unit.
Each PubCo Unit consists of (i) one PubCo Ordinary Share and (ii) one series A preferred share of PubCo, par value $0.00001 per share (the PubCo Preferred Shares ).
Each PubCo Preferred Share will be converted into one-third (1/3) of one PubCo Ordinary Share on the six-month anniversary of the closing of the Business Combination.
REMOVED
As of March 24, 2025, there were 9,080,000 ordinary shares of the Company, par value $0.0001 per share issued and outstanding.
We have not selected any target business for our initial business combination.
(NASDAQ: LBBB), and the Chairman, Chief Executive Officer, Chief Financial Officer and Director of Horizon Space Acquisition I Corp.
We have until November 18, 2025 to consummate an initial business combination.
However, if we anticipate that we may not be able to consummate our initial business combination by November 18, 2025, we may extend the period of time to consummate a business combination up to two times, each time by an additional three months (up to May 18, 2026 to complete a business combination) (the Combined Period ) without submitting such proposed extensions to our shareholders for approval or offering our public shareholders redemption rights in connection therewith.
Pursuant to the terms of our amended and restated memorandum and articles of association and the Investment Management Trust Agreement, dated November 14, 2024 between us and Wilmington Trust, N.A, as trustee, in order to extend the time available for us to consummate our initial business combination, the Sponsor or its affiliates or designees, upon five days advance notice prior to the applicable deadline, must deposit into the Trust Account $690,000 on or prior to the date of the applicable deadline, for each three month extension (or up to an aggregate of $1,380,000) (the Extension Fee ).
We have not selected any target business for our initial business combination.
For the period from March 21, 2023 (inception) through December 31, 2023, we had a net loss of $4,255, all of which consisted of formation and operating costs.
Liquidity and Capital Resources As of December 31, 2024, the Company had cash of $646,720 and working capital of $450,875.
The Company is currently evaluating the impact of the pending adoption of ASU 2023-09 on its financial statements.